– UK, Warrington – Assura plc (LSE:AGR), the leading investor and developer of primary care properties, announces today that Jonathan Davies has been appointed to the Board as Non-Executive Director with effect from 1 June 2018.
Jonathan Davies is Chief Financial Officer of SSP Group plc. He has been CFO of SSP since 2004. Prior to this he was Finance Director, Operations Board of Safeway plc, and before this worked at OC&C Strategy Consultants and Unilever plc. He has an MBA from INSEAD and a degree in Chemistry from Oxford University. Jonathan Davies will join all board committees.
Simon Laffin, Chairman of Assura, commented: “Jonathan has excellent financial experience, both operational and corporate. Together with his strategic thinking and personal commitment to the NHS, he will also contribute significantly to the board as Assura continues to fund the transformation of NHS primary care premises.”
Commenting on his appointment, Jonathan Davies said: “I’m delighted to be joining the board of Assura, which is a very strong business, performing an exceptionally important role in supporting the NHS primary care system, and is well positioned for future growth.”
About Assura plc
Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create innovative property solutions in order to facilitate delivery of high quality patient care in the community. At 31 March 2018, Assura’s property portfolio was valued at £1,733 million.
For more information : https://www.assuraplc.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
